Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

441. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US Cost-effectiveness model of long-acting risperidone in schizophrenia in the US Cost-effectiveness model of long-acting risperidone in schizophrenia in the US Edwards N C, Rupnow M F T, Pashos C L, Botteman M F, Diamond R J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of a long-acting injection (LAI) formulation of risperidone (RIS) for the treatment of patients with schizophrenia. Patients could receive LAI RIS 25 mg, 37.5 mg or 50 mg, given at 14-day intervals. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of community

2005 NHS Economic Evaluation Database.

442. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA

of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. PharmacoEconomics 2005; 23(Supplement 1): 75-89 PubMedID Other publications of related interest Glazer WM, Ereshefsky LA. Pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 1996;57:337-45. Indexing Status Subject indexing assigned by NLM MeSH Antipsychotic Agents /administration & Cost of Illness; Cost-Benefit (...) Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA Edwards N C, Locklear J C, Rupnow M F, Diamond R J Record Status This is a critical

2005 NHS Economic Evaluation Database.

443. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis

The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

444. Case studies of adjunctive agents in clozapine-resistant schizophrenic patients

schizophrenic patients. Clinical Neuropharmacology 2005; 28(1): 50-53 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adjuvants, Pharmaceutic /therapeutic use; Adolescent; Adult; Clozapine /therapeutic use; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Risperidone /therapeutic use; Schizophrenia /drug therapy AccessionNumber 12005006302 Date bibliographic record published 31/01/2007 Date abstract record published 31/01/2007 Record Status This is a critical abstract (...) Case studies of adjunctive agents in clozapine-resistant schizophrenic patients Case studies of adjunctive agents in clozapine-resistant schizophrenic patients Case studies of adjunctive agents in clozapine-resistant schizophrenic patients Kontaxakis V P, Ferentinos P P, Havaki-Kontaxaki B J, Paplos K G, Roukas D K, Christodoulou G N CRD summary This review examined case studies of the efficacy and safety of adjunctive agents in clozapine-resistant schizophrenic or schizoaffective patients

2005 DARE.

445. Healthy living interventions and schizophrenia: a systematic review

Healthy living interventions and schizophrenia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

446. There is fair (2b) level evidence that living skills training is effective at improving independence in food preparation, money management, personal possessions, and efficacy, in adults with persistent schizophrenia

There is fair (2b) level evidence that living skills training is effective at improving independence in food preparation, money management, personal possessions, and efficacy, in adults with persistent schizophrenia otcats.com - otcats Resources and Information. This Domain Name Has Expired - .

2004 Publication 315

447. Paternal age and schizophrenia: a population based cohort study. Full Text available with Trip Pro

Paternal age and schizophrenia: a population based cohort study. To investigate the association of paternal age at conception with the risk of offspring developing schizophrenia.A population based cohort study.Sweden.754,330 people born in Sweden between 1973 and 1980 and still alive and resident in Sweden at age 16 years.Hospital admission with schizophrenia or non-schizophrenic, non-affective psychosis.After adjustment for birth related exposures, socioeconomic factors, family history (...) of psychosis, and early parental death the overall hazard ratio for each 10 year increase in paternal age was 1.47 (95% confidence interval 1.23 to 1.76) for schizophrenia and 1.12 (0.98 to 1.29) for non-schizophrenic non-affective psychosis. This association between paternal age and schizophrenia was present in those with no family history of the disorder (hazard ratio for each 10 year increase in paternal age 1.60, 1.32 to 1.92), but not in those with a family history (0.91, 0.44 to 1.89) (P = 0.04

2004 BMJ

448. Review: the case for antidepressants for treating depression in people with schizophrenia remains unproven Full Text available with Trip Pro

Review: the case for antidepressants for treating depression in people with schizophrenia remains unproven Review: the case for antidepressants for treating depression in people with schizophrenia remains unproven | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: the case for antidepressants for treating depression in people with schizophrenia remains unproven Article Text Therapeutics Review: the case for antidepressants

2004 Evidence-Based Mental Health

449. Targeted cognitive behavioural therapy may reduce relapse in people with prodromal symptoms of schizophrenia Full Text available with Trip Pro

Targeted cognitive behavioural therapy may reduce relapse in people with prodromal symptoms of schizophrenia Targeted cognitive behavioural therapy may reduce relapse in people with prodromal symptoms of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Targeted cognitive behavioural therapy may reduce relapse in people with prodromal symptoms of schizophrenia Article Text Therapeutics Targeted cognitive behavioural therapy may

2004 Evidence-Based Mental Health

450. Parents of adult children with schizophrenia dealt with societal objections in order to provide the necessary care Full Text available with Trip Pro

Parents of adult children with schizophrenia dealt with societal objections in order to provide the necessary care Parents of adult children with schizophrenia dealt with societal objections in order to provide the necessary care | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Parents of adult children with schizophrenia dealt with societal objections in order to provide the necessary care Article Text Qualitative Parents of adult children

2004 Evidence-Based Nursing

451. Amphetamines for schizophrenia. (Abstract)

Amphetamines for schizophrenia. It is estimated that between 10% and 65% of people with schizophrenia use illicit drugs such as amphetamines. This group have an increased rate of hospitalisation, homelessness, unemployment and suicide compared with those with schizophrenia who do not abuse drugs.To evaluate the effects of amphetamines for people with schizophrenia in terms of clinically meaningful outcomes, cognitive functioning and physiological tests.We searched the Cochrane Schizophrenia (...) Group's Register (February 2002).We included all randomised controlled trials investigating the effects of amphetamines on people with schizophrenia, compared with a placebo intervention.Working independently, we selected and critically appraised studies, extracted data and analysed on an intention-to-treat basis. Where possible and appropriate we calculated risk ratios (RR) and their 95% confidence intervals (CI), with the number needed to treat (NNT). For continuous data we calculated Weighted Mean

2004 Cochrane

452. Antipsychotic medication versus placebo for people with both schizophrenia and learning disability. (Abstract)

Antipsychotic medication versus placebo for people with both schizophrenia and learning disability. Antipsychotic medication is the standard treatment for people with learning disability and schizophrenia.To determine the effects of any antipsychotic medication compared with placebo for treating people with a dual diagnosis of learning disability and schizophrenia.For this update we searched the Cochrane Schizophrenia Group's Register of trials (July 2004), relevant reference lists and sought (...) unpublished data from pharmaceutical companies.We included all randomised clinical trials of longer than one month's duration, involving people with both schizophrenia and learning disability (a measured IQ of 70 or less) that evaluated antipsychotic medication versus placebo.We reliably selected and assessed studies for methodological quality. Two reviewers, working independently, extracted data. We would have analysed dichotomous data on an intention-to-treat basis and presented continuous data with 65

2004 Cochrane

453. People with schizophrenia believe that they are stigmatised at work and in the community Full Text available with Trip Pro

, Dr, Director Statistics from Altmetric.com Schulze B, Angermeyer MC. Subjective experiences of stigma. A focus group study of schizophrenic patients, their relatives and mental health professionals. Soc Sc Med 2003 Feb; 56 : 299 –312 QUESTION: How does stigma affect the everyday lives of people with schizophrenia? Design Cross sectional focus group study. Setting 4 German outpatient centres involved in the “WPA Global Programme against Stigma and Discrimination because of Schizophrenia (...) People with schizophrenia believe that they are stigmatised at work and in the community People with schizophrenia believe that they are stigmatised at work and in the community | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers

2004 Evidence-Based Mental Health

454. Clozapine may be more effective than olanzapine for reducing suicidal behaviour in people with schizophrenia at high risk Full Text available with Trip Pro

Clozapine may be more effective than olanzapine for reducing suicidal behaviour in people with schizophrenia at high risk Clozapine may be more effective than olanzapine for reducing suicidal behaviour in people with schizophrenia at high risk | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clozapine may be more effective than olanzapine for reducing suicidal behaviour in people with schizophrenia at high risk Article Text

2004 Evidence-Based Mental Health

455. Review: women with schizophrenia have poorer pregnancy outcomes than other women, but it is unclear whether antipsychotic medications affect their infants Full Text available with Trip Pro

Review: women with schizophrenia have poorer pregnancy outcomes than other women, but it is unclear whether antipsychotic medications affect their infants Review: women with schizophrenia have poorer pregnancy outcomes than other women, but it is unclear whether antipsychotic medications affect their infants | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: women with schizophrenia have poorer pregnancy outcomes than other

2004 Evidence-Based Mental Health

456. Review: lifetime prevalence of schizophrenia and related disorders is about 5.5 per 1000, but there is significant variation between regions Full Text available with Trip Pro

, but there is significant variation between regions Article Text Prevalence Review: lifetime prevalence of schizophrenia and related disorders is about 5.5 per 1000, but there is significant variation between regions Free Jan Olav Johannessen , MD , Chief Psychiatrist Statistics from Altmetric.com Goldner E M et al. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry. 2002 Nov; 47 : 833 –43 QUESTION: What is the prevalence of schizophrenia and related (...) that there is variation in the distribution of schizophrenia around the world. Subtle methodological differences, such as discrepancies in diagnostic practices between studies, cannot be ruled out as an explanation for variations in prevalence rates. COMMENTARY There is growing recognition that the incidence of schizophrenic disorders varies between geographical areas. It is unlikely that this variance is due to migration. This raises important questions about both the aetiology of schizophrenia and the treatment

2004 Evidence-Based Mental Health

457. Change in suicide rates for patients with schizophrenia in Denmark, 1981-97: nested case-control study. Full Text available with Trip Pro

Change in suicide rates for patients with schizophrenia in Denmark, 1981-97: nested case-control study. To study the change in risk of suicide among patients with schizophrenia and related disorders.Nested case-control design with linked data.4 longitudinal Danish registers.18,744 people aged up to 75 years who committed suicide in 1981-97 individually matched with 20 controls.Over the time studied the reduction in suicide rate among patients with schizophrenia and schizophrenia spectrum (...) disorder was similar to that seen in the general population (incidence rate ratio 1.00, 95% confidence interval 0.98 to 1.03). The reduction among patients with other psychosis in the schizophrenia spectrum was faster than the reduction seen in the general population. Among people admitted to hospital with schizophrenia the risk of suicide was highest in the first year after first admission, and the excess risk was largest in the younger age groups-that is, the risk decreased per year for every

2004 BMJ

458. Schizophrenia. (Abstract)

Schizophrenia. Schizophrenia is a mental illness that is among the world's top ten causes of long-term disability. The symptoms of schizophrenia include psychosis, apathy and withdrawal, and cognitive impairment, which lead to problems in social and occupational functioning, and self-care. About 1% of the population is affected by schizophrenia, with similar rates across different countries, cultural groups, and sexes. The illness tends to develop between the ages of 16 and 30 years, and mostly (...) persists throughout the patient's lifetime. The cause of schizophrenia is unknown, but evidence suggests that genetic factors, early environmental influences (eg, obstetric complications), and social factors (eg, poverty) contribute. No biological alterations are pathognomonic of schizophrenia, although several pathophysiological differences exist in a wide range of brain structures. Antipsychotic medications are the mainstay for managing schizophrenia. A range of psychosocial treatments are also

2004 Lancet

459. Aripiprazole for schizophrenia. (Abstract)

Aripiprazole for schizophrenia. Treatment of people with schizophrenia using older typical antipsychotic drugs such as haloperidol can be problematic. Many fail to respond and more experience disabling adverse effects. Aripiprazole is said to be one of a new generation of atypical antipsychotics with good antipsychotic properties and minimal adverse effects.To evaluate the effects of aripiprazole for people with schizophrenia and schizophrenia-like psychoses.The reviewers searched the Cochrane (...) Schizophrenia Group's Register (May 2003) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. References of all identified studies were inspected for further trials. The authors contacted relevant pharmaceutical companies, the FDA and authors of trials for additional information.All clinical randomised trials comparing aripiprazole with placebo, typical or atypical antipsychotic drugs for schizophrenia and schizophrenia-like psychoses.We extracted data independently

2004 Cochrane

460. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Full Text available with Trip Pro

Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Medication used for acute aggression in psychiatry must have rapid onset of effect, low frequency of administration and low levels of adverse effects. Zuclopenthixol acetate is said to have these properties.To estimate the clinical effects of zuclopenthixol acetate for the management of acute aggression or violence thought to be due to serious mental illnesses, in comparison to other drugs used to treat similar (...) conditions.We supplemented past searches of Current Controlled Trials (10/2000), the Cochrane Library (1997) and MEDLINE (1966-1997) and appeals for unpublished data with an update search of the Cochrane Schizophrenia Group's Register of trials (September 2003).All randomised clinical trials involving people thought to have serious mental illnesses comparing zuclopenthixol acetate with other drugs.Data were extracted independently by two reviewers and cross-checked. We calculated fixed effects relative

2004 Cochrane